PHIO
Price
$2.99
Change
+$0.53 (+21.54%)
Updated
Jun 6, 04:35 PM (EDT)
Capitalization
11.8M
SLRX
Price
$0.74
Change
-$0.01 (-1.33%)
Updated
Jun 6, 04:34 PM (EDT)
Capitalization
1.6M
Interact to see
Advertisement

PHIO vs SLRX

Header iconPHIO vs SLRX Comparison
Open Charts PHIO vs SLRXBanner chart's image
Phio Pharmaceuticals
Price$2.99
Change+$0.53 (+21.54%)
Volume$2.51K
Capitalization11.8M
Salarius Pharmaceuticals
Price$0.74
Change-$0.01 (-1.33%)
Volume$100
Capitalization1.6M
PHIO vs SLRX Comparison Chart
Loading...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHIO vs. SLRX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHIO is a Buy and SLRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (PHIO: $2.46 vs. SLRX: $0.75)
Brand notoriety: PHIO and SLRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHIO: 155% vs. SLRX: 33%
Market capitalization -- PHIO: $11.8M vs. SLRX: $1.6M
PHIO [@Biotechnology] is valued at $11.8M. SLRX’s [@Biotechnology] market capitalization is $1.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHIO’s FA Score shows that 0 FA rating(s) are green whileSLRX’s FA Score has 0 green FA rating(s).

  • PHIO’s FA Score: 0 green, 5 red.
  • SLRX’s FA Score: 0 green, 5 red.
According to our system of comparison, PHIO is a better buy in the long-term than SLRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHIO’s TA Score shows that 4 TA indicator(s) are bullish while SLRX’s TA Score has 5 bullish TA indicator(s).

  • PHIO’s TA Score: 4 bullish, 4 bearish.
  • SLRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both PHIO and SLRX are a good buy in the short-term.

Price Growth

PHIO (@Biotechnology) experienced а +20.59% price change this week, while SLRX (@Biotechnology) price change was -4.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

PHIO is expected to report earnings on Mar 31, 2025.

SLRX is expected to report earnings on Mar 21, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHIO($11.8M) has a higher market cap than SLRX($1.6M). PHIO YTD gains are higher at: 36.667 vs. SLRX (-59.043). SLRX has higher annual earnings (EBITDA): -5.21M vs. PHIO (-7.41M). PHIO has more cash in the bank: 5.39M vs. SLRX (3.28M). PHIO has less debt than SLRX: PHIO (0) vs SLRX (329K). PHIO (0) and SLRX (0) have equivalent revenues.
PHIOSLRXPHIO / SLRX
Capitalization11.8M1.6M736%
EBITDA-7.41M-5.21M142%
Gain YTD36.667-59.043-62%
P/E Ratio0.01N/A-
Revenue00-
Total Cash5.39M3.28M164%
Total Debt0329K-
FUNDAMENTALS RATINGS
PHIO vs SLRX: Fundamental Ratings
PHIO
SLRX
OUTLOOK RATING
1..100
2965
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
4965
P/E GROWTH RATING
1..100
66100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHIO's Valuation (58) in the Biotechnology industry is in the same range as SLRX (80) in the null industry. This means that PHIO’s stock grew similarly to SLRX’s over the last 12 months.

PHIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SLRX (100) in the null industry. This means that PHIO’s stock grew similarly to SLRX’s over the last 12 months.

PHIO's SMR Rating (96) in the Biotechnology industry is in the same range as SLRX (96) in the null industry. This means that PHIO’s stock grew similarly to SLRX’s over the last 12 months.

PHIO's Price Growth Rating (49) in the Biotechnology industry is in the same range as SLRX (65) in the null industry. This means that PHIO’s stock grew similarly to SLRX’s over the last 12 months.

PHIO's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for SLRX (100) in the null industry. This means that PHIO’s stock grew somewhat faster than SLRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHIOSLRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HBIO0.41N/A
+0.44%
Harvard Bioscience
HAYW14.180.03
+0.21%
Hayward Holdings
TMCI5.780.01
+0.17%
Treace Medical Concepts
SYF57.45-0.42
-0.73%
Synchrony Financial
BCDA2.13-0.04
-1.84%
BioCardia Inc.

PHIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been loosely correlated with MTNB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PHIO jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
+17.14%
MTNB - PHIO
50%
Loosely correlated
+5.67%
TPST - PHIO
49%
Loosely correlated
+15.16%
SAGE - PHIO
42%
Loosely correlated
+3.44%
IMNN - PHIO
39%
Loosely correlated
-16.47%
SLRX - PHIO
36%
Loosely correlated
-3.36%
More

SLRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLRX has been closely correlated with MBIO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if SLRX jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLRX
1D Price
Change %
SLRX100%
-3.36%
MBIO - SLRX
71%
Closely correlated
-3.19%
AZTR - SLRX
40%
Loosely correlated
-2.00%
PHIO - SLRX
35%
Loosely correlated
+17.14%
NRSN - SLRX
32%
Poorly correlated
+1.18%
KNSA - SLRX
29%
Poorly correlated
+2.29%
More